WO2005089804A3 - Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists - Google Patents

Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists Download PDF

Info

Publication number
WO2005089804A3
WO2005089804A3 PCT/IB2005/000574 IB2005000574W WO2005089804A3 WO 2005089804 A3 WO2005089804 A3 WO 2005089804A3 IB 2005000574 W IB2005000574 W IB 2005000574W WO 2005089804 A3 WO2005089804 A3 WO 2005089804A3
Authority
WO
WIPO (PCT)
Prior art keywords
combinations
hmg
receptor antagonists
coa reductase
adrenergic receptor
Prior art date
Application number
PCT/IB2005/000574
Other languages
French (fr)
Other versions
WO2005089804A2 (en
Inventor
Nicholas Pullen
Richard James Thurlow
Original Assignee
Pfizer Ltd
Pfizer
Nicholas Pullen
Richard James Thurlow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0405904A external-priority patent/GB0405904D0/en
Application filed by Pfizer Ltd, Pfizer, Nicholas Pullen, Richard James Thurlow filed Critical Pfizer Ltd
Publication of WO2005089804A2 publication Critical patent/WO2005089804A2/en
Publication of WO2005089804A3 publication Critical patent/WO2005089804A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)

Abstract

Combinations of an HMG-CoA reductase inhibitor, other than atorvastatin, and α1 adrenergic receptor antagonists, the use of such combinations in the treatment of benign prostatic hyperplasia (BPH), methods of treating BPH using such combinations and medicaments containing such combinations are described.
PCT/IB2005/000574 2004-03-16 2005-03-04 Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists WO2005089804A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0405904A GB0405904D0 (en) 2004-03-16 2004-03-16 Combinations of hmg-coa reductase inhibitors and x1 adrenergic receptor antagonists
GB0405904.4 2004-03-16
US56365004P 2004-04-20 2004-04-20
US60/563,650 2004-04-20

Publications (2)

Publication Number Publication Date
WO2005089804A2 WO2005089804A2 (en) 2005-09-29
WO2005089804A3 true WO2005089804A3 (en) 2006-05-18

Family

ID=34960808

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000574 WO2005089804A2 (en) 2004-03-16 2005-03-04 Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists

Country Status (1)

Country Link
WO (1) WO2005089804A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1238011B (en) * 1989-12-13 1993-06-21 Pulitzer Italiana Pharmaceutical composition with an HMG - COA reductase inhibitor base, for treatment of benign prostatic hypertrophy (enlarged prostate gland)
WO1998030560A1 (en) * 1997-01-11 1998-07-16 Pfizer Limited Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia
WO2001064672A1 (en) * 2000-03-03 2001-09-07 Pfizer Limited 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs
US20020004521A1 (en) * 2000-01-07 2002-01-10 Kenneth Weisman Use of HMG-COA reductase inhibitors to prevent and treat BPH
WO2003076427A1 (en) * 2002-03-14 2003-09-18 Pfizer Limited Quinazoline compounds useful in therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1238011B (en) * 1989-12-13 1993-06-21 Pulitzer Italiana Pharmaceutical composition with an HMG - COA reductase inhibitor base, for treatment of benign prostatic hypertrophy (enlarged prostate gland)
WO1998030560A1 (en) * 1997-01-11 1998-07-16 Pfizer Limited Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia
US20020004521A1 (en) * 2000-01-07 2002-01-10 Kenneth Weisman Use of HMG-COA reductase inhibitors to prevent and treat BPH
WO2001064672A1 (en) * 2000-03-03 2001-09-07 Pfizer Limited 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs
WO2003076427A1 (en) * 2002-03-14 2003-09-18 Pfizer Limited Quinazoline compounds useful in therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOODMAN GILMAN A ET AL: "The pharmacological basis of therapeutics, PASSAGE", GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, NEW YORK : MCGRAW-HILL, US, 2001, pages 246 - 248, XP002297699, ISBN: 0-07-135469-7 *

Also Published As

Publication number Publication date
WO2005089804A2 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
WO2008019139A3 (en) Inhibitors of pyruvate kinase and methods of treating disease
TNSN07385A1 (en) Therapeutic combination in case of benign prostate hyperplasia
EP1887976A4 (en) Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
GEP20074122B (en) Treating benign prostate hyperplasia with selective androgen receptor modulators
WO2006045119A3 (en) Improved inhibitors for the soluble epoxide hydrolase
WO2000043032A3 (en) Baff, inhibitors thereof and their use in the modulation of b-cell response
WO2004030625A3 (en) Synergistic methods and compositions for treating cancer
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
WO2004004644A3 (en) Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
WO2003075841A3 (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
EA200400029A1 (en) ANTAGONIST COMBINATION OF ALCHOSTERONE RECEPTOR AND HMG-COA REDUCTASE INHIBITOR
WO2004093826A3 (en) Compositions of cyclooxygenase-2 selective inhibitors and 5-ht1b/1d agonists for the treatment and prevention of migraine
WO2007051065A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
WO2004105757A3 (en) Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
WO2005110479A3 (en) Treatments for pancreatic cancer
EP2026877A4 (en) Benign prostatic hyperplasia treatment device and method
WO2004103960A3 (en) Compounds and uses thereof
TW200801008A (en) Protein kinase inhibitors
IS5093A (en) Quinoline and quinazoline compounds useful in the treatment, especially for the treatment of benign prostatic hyperplasia
WO2004089296A3 (en) Improved inhibitors for the soluble epoxide hydrolase
WO2006121719A3 (en) Soluble epoxide hydrolase inhibitors and methods of using same
WO2006071644A8 (en) Selective inhibitors of erk protein kinases and uses therof
AU2003233223A1 (en) Utilization of inhibitors of egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph)/prostatic hypertrophy
EP2030615A3 (en) Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
ECSP077247A (en) TRANS - CLOMPHENE FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY, PROSTATIC CANCER, HYPOGONODISM, HIGH TRIGLICERIDS AND HIGH CHOLESTEROL

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase